Key takeaways
- The UK is the first European nation to approve Eli Lilly's once-daily oral GLP-1 drug, Foundayo, for weight loss and type 2 diabetes.
- Foundayo will launch privately in the UK later this month, priced below the £330 monthly cost of injectable Mounjaro.
- Unlike Novo Nordisk's oral Wegovy, Foundayo does not require strict food or water restrictions, offering superior convenience.
- The expansion of brand-name oral GLP-1s signals a future shift toward needle-free options for US telehealth consumers.
What happened
On August 10, 2026, Britain's Medicines and Healthcare products Regulatory Agency (MHRA) officially authorized Eli Lilly's once-daily weight-loss pill, Foundayo, for weight management and type 2 diabetes. This regulatory milestone makes the United Kingdom the first country in Europe to greenlight the oral treatment for both conditions.
Why it matters
The authorization of Foundayo in the UK intensifies the high-stakes global race between Eli Lilly and Novo Nordisk to commercialize convenient, needle-free obesity medications. While weekly injections like Wegovy and Zepbound currently dominate the weight-loss market, oral tablets represent the next frontier for patient accessibility. For US consumers, who often seek more convenient options through online telehealth platforms, the expansion of oral alternatives overseas signals an impending shift in how these medications will be prescribed, priced, and delivered digitally in the near future.
What the data says
According to the MHRA and details reported by Reuters, Foundayo is a once-daily tablet targeting the GLP-1 receptor. Unlike Novo Nordisk’s oral Wegovy option—which requires patients to take the pill on an empty stomach with a small sip of water and wait 30 minutes before eating or drinking—Foundayo can be taken without food or water restrictions.
A spokesperson for Eli Lilly confirmed that Foundayo will launch in the UK later this month via private prescription. While it will not initially be available through the National Health Service (NHS), the pill is expected to carry a lower private list price than Lilly’s injectable Mounjaro, which currently lists at £330 (approximately $425 USD) for a monthly supply in the UK.
In comparison, Eli Lilly’s oral drug has been gaining commercial momentum in the US since its domestic approval in April 2026. However, it still lags behind Novo Nordisk’s market share in the oral segment.
How it compares
The major advantage Foundayo holds over Novo Nordisk's oral Wegovy pill comes down to daily dosing flexibility. For telehealth buyers who value simplicity, skipping the strict 30-minute morning fasting window required by Novo's tablet is a significant clinical convenience.
For US buyers shopping via online telehealth providers, the introduction of brand-name oral options will eventually challenge the current dominance of compounded liquid peptides. Currently, patients looking for needle-free options on platforms listed in our telehealth provider directory frequently rely on sublingual compounded drops or daily oral sublingual suspensions. Once brand-name pills like Foundayo and oral Wegovy achieve widespread insurance coverage and distribution, they could alter the price math for patients paying out-of-pocket, who currently spend anywhere from $150 to $400 per month for compounded alternatives.
How this fits the bigger picture
The UK approval of Foundayo is part of a broader regulatory chess match between Eli Lilly and Novo Nordisk. In June 2026, the UK approved Novo's oral Wegovy pill, meaning Lilly's latest approval directly answers its rival’s European expansion.
This development aligns closely with our previous coverage on the FDA approval of the oral Wegovy pill, which highlighted how a needle-free path would transform the telehealth landscape. As both pharmaceutical giants secure global approvals for their oral portfolios, they are systematically building out alternative pipelines to bypass injection-related manufacturing bottlenecks.
Furthermore, as we explored in our analysis of Novo Nordisk's multi-drug obesity strategy, the transition to oral small-molecule drugs allows manufacturers to scale up production much faster than complex biologic injections. This shift could eventually ease the chronic supply constraints that have plagued the market, offering a more stable supply chain for both traditional pharmacy buyers and digital health platforms.
What happens next
Following this UK approval, Eli Lilly is preparing to launch Foundayo via private British prescriptions by the end of August 2026. Meanwhile, the drug remains under regulatory review in the European Union.
Novo Nordisk is also waiting on a final European Commission approval decision for its oral Wegovy pill, following a positive recommendation from the European Medicines Agency (EMA). As these oral therapies establish a commercial foothold in Europe, US clinical guidelines and telehealth platforms are expected to increasingly adapt their prescribing intake flows to accommodate patients who prefer a daily pill over a weekly injection.
Disclaimer: CompareRx does not provide medical advice. Always consult with a licensed healthcare provider before starting or switching any weight-loss medication.